1Department of Gastroenterology, Azienda Ospedaliero-Universitaria and University of Modena and Reggio Emilia, 41124 Modena, Italy.
2Department of Medical and Surgical Sciences, University of Bologna and Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant’Orsola Malpighi, 40138 Bologna, Italy.
Correspondence Address: Prof. Pietro Andreone, Department of Medical and Surgical Sciences, University of Bologna and Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant’Orsola Malpighi, Via Massarenti 9, 40138 Bologna, Italy. E-mail: firstname.lastname@example.org
Professor Pietro Andreone is the Director of the Program for the Diagnosis and Treatment of Chronic Viral Hepatitis at the University Hospital of Bologna, Italy. He has been the principal investigator in over 100 clinical studies in the field of innovative therapies for chronic hepatitis and has published 197 peer reviewed publications with a h-index of 42.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License (http://creativecommons.org/licenses/by-nc-sa/3.0/), which allows others to remix, tweak and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
In the last decade, the incidence of hepatocellular carcinoma (HCC) is growing in both Europe and United States. Conventional therapies such as liver resection, transplantation, ablation, chemoembolization and sorafenib are not enough to avoid a significant mortality. Many studies suggested the positive effect of caffeine for prevention of HCC. Nevertheless, the amount of therapeutic caffeine and the high-dose safety are unknown. Many authors proposed Traditional Chinese Medicine as preventive and/or curative approach. Although it reveals limits such as the uncertain safety profile and the lack of evidence about a unique product, it shows interesting results in terms of survival and quality of life if given in combination with standard loco-regional therapy. Among the future promises, cannabinoids show interesting background mechanisms of blocking cell proliferation and neoangiogenesis. It is conceivable that in the next years, some natural products may have a role in improving the standards of care of HCC.
Hepatocellular carcinoma, caffeine, Traditional Chinese Medicine, cannabinoids
Liver neoplasm represents the sixth most common cancer and the third cause of cancer-related mortality worldwide. Hepatocellular carcinoma (HCC) is the main liver cancer, accounting for more than 90% of cases of liver tumors. In the last decades, the HCC incidence and HCC-related mortality are increasing in both United States and Northern Europe. Cirrhosis due to chronic hepatitis B and C, is the major risk factor for the HCC development. However, also other potentially risky conditions such as alcohol intake, tobacco habit, overweight, diabetes, aflatoxin consumption and oral contraceptives use, should be considered.
Barcelona-Clinic Liver Cancer (BCLC) staging system is a widely used set of criteria to guide management of patients with HCC. It takes into account tumor stage, liver functional status, physical status and cancer-related symptoms. Surgical treatment of HCC is a potentially curative approach, including liver transplantation (LT) and liver resection. LT is the best treatment option for patients fitting the “Milan criteria” since it removes both neoplasm and underlying liver disease. For patients with single tumor < 2 cm, with a Child-Turcotte-Pugh class A, without clinically significant portal hypertension and with normal bilirubin, liver resection represents a feasible strategy. Ablation with ethanol or acetic acid or thermal, is another potentially curative option. It is practicable in patients with single, small tumors not candidates for surgery. Many HCC cases are diagnosed in stage B of BCLC algorithm, for which the standard of care is the transcatheter arterial chemoembolization (TACE). Lastly, sorafenib is the unique universally approved systemic palliative drug for BCLC C patients.
In the European and in the North-American guidelines, no natural product is mentioned neither for the prophylaxis nor for the treatment of HCC. On the contrary, in the Asian-Pacific ones, natural products are cited for both primary and secondary prophylaxis.
Literature data are available regarding the coffee-derived substances as prevention tools in high-risk populations, the possible prevention or adjuvant effect of many kinds of Traditional Chinese Medicine (TCM), and possible utility of cannabinoids as antineoplastic drugs.
Hereby, we sought to review the current knowledge on the role of some natural products in the prevention and treatment of HCC. The research included published articles (peer reviewed original articles, review articles and meta-analyses). The search terms included “natural products and hepatocellular carcinoma”, “natural products and liver”, “hepatocellular carcinoma treatment options”, “coffee and HCC”, “Traditional Chinese Medicine and HCC”, and “cannabinoids and HCC”.
Many data are available about the dose-dependent protective effect of coffee respect to the development of liver disease and HCC. Both in vitro and in vivo studies showed that several coffee compounds such as diterpenes, cafestol and kahweol, may act on some enzymes involved in carcinogenesis.[9,10] Diterpenes, cafestol and kahweol seem to modify the xenotoxic metabolism via induction of glutathione-S-transferase and inhibition of N-acetyltransferase. Caffeine and antioxidant substances from coffee beans, may improve some liver enzymes, such as γ-glutamyltransferase and aminotransferase. Interestingly, this positive effect of caffeine is mainly relevant in heavy drinkers.[12,13] Notably, coffee consumption would be inversely related to the hazard of cirrhosis, which is the main risk factor of HCC.[14,15]
In an Italian case-control study (including 250 HCC), coffee intake showed a significant protective role against HCC. In all patients, ten-year coffee intake was associated with a decreased risk of HCC with a dose-effect relation (double with 3-4 cups/day respect to 1-2 cups/day).
In a further Italian study (185 HCC), patients drinking ≥ 4 cups/day (no decaffeinated) had a lesser risk of HCC respect to the others.
Tanaka et al. developed a Japanese case-control study (209 HCC) showing that coffee consumption during the last 1-2 years, was associated with a decreased risk of HCC. Another Japanese case-control study including 73 HCC, analyzed the role of coffee in patients with hepatitis C. Coffee drinking ≥ 1 cup/day significantly reduced the risk of HCC compared to the abstinence. The same data were found for hepatitis B chronic carriers with a risk reduction of 30-80%.
Two large Japanese prospective studies[23-24] including hepatitis B, C and sieronegative subjects, reported that drinkers of ≥ 5 cups/day had a lower dose-dependent HCC risk respect to abstinent patients.
The relationship between coffee and risk of HCC was studied also by Johnson et al. through a large prospective study including 63,257 patients. The authors reported that subjects consuming ≥ 3 cups/day experienced a 44% of HCC risk reduction.
Hu et al. firstly analyzed the possible association between coffee consumption, serum gamma-glutamyltransferase and HCC. The study cohorts included 60,323 patients without cancer. During a median follow-up period of 19.3 years, 128 participants developed HCC. According to the author’s data, a combination of very low coffee consumption and high level of serum GGT was associated with nearly nine-fold increased risk of HCC.
In 2007, Bravi et al. performed a meta-analysis based on 10 studies (both European and Asian) and a total of 2,260 HCC cases. Authors reported a 41% of reduction in HCC risk among coffee drinkers compared to non-drinkers. In the same year, Larsson et al. published another meta-analysis with similar conclusions. In 2013, Bravi et al. conducted a further meta-analysis including more recent studies. According to the authors, coffee drinkers had a decrease of 40% in the risk of HCC compared to abstinent patients. Moreover, high coffee drinkers showed more than 50% of risk drop. Notably, the protective effect of coffee was reliable across different subgroups at increased HCC risk.
After the publication of these meta-analyses, other studies regarding the protective role of coffee in the HCC setting have been published. The first one, was a multicentre study by Bamia et al. including 201 HCC cases. Authors demonstrated that coffee intake was associated with a decrease of 72% in HCC risk. Setiawan et al. conducted a large population-based prospective cohort study (451 HCC) showing that drinkers of 2-3 cups/day respect to abstinent subjects, had a 38% of HCC risk reduction. In addiction, patients drinking 4 or more cups/day had a 41% of risk drop. Feld et al. again suggested that regular ingestion of coffee in patients with chronic liver disease can make slower the progression of liver fibrosis, preventing both cirrhosis and HCC. Petrick et al. developed the Liver Cancer Pooling Project based on North-American data and including 1,212,893 patients (with 860 HCC cases). A high caffeinated coffee consumption (≥ 4 cups/day) was associated with a lower risk of HCC in comparison to a lesser intake. In a Japanese cohort-study including 258 cases, an inverse association was reported between coffee and mortality associated to HCC. Interestingly, the hazard of HCC-related death for abstinent patients was two-fold higher compared to coffee drinkers, and this was true also for few consumption (≥ 1 cup/day).
Many authors proposed TCM-based therapy alone or in combination with standard loco-regional therapies for prevention or treatment of HCC [Table 1]. The main TCM products include combinations of different herbal medicines or animal/insect extracts. Astragalus shows immunomodulatory properties and anti-tumor activity. It seems to reinforce Lymphokine Activated Killer cell activity restoring the T-cell function suppressed in cancer patients.[35,36] The Panax Ginseng has inhibitory effects on cell proliferation and angiogenesis restraining tumor cell invasion and defeating sister chromatid interactions in human lymphocytes. Toad skin secretion bufalin (Bufotoxin) could induce apoptosis in human-leukaemia cells modifying the expression of some apoptotic genes. Other toad skin secretions such as 3-formyloxyresibufogenin, 19-oxobufalin, 19-oxodesacetylcinobufagin, 6-hydroxycinobufagin and 1-hydroxybufalin seem to have inhibitory properties on KB, human promyelocytic leukemia cells (HL-60) and MH-60 cancer cell lines.Mylabris phaleratais (Mylabris) can lead to the apoptosis of tumor cells while Atractylodes might bring apoptosis and have cytotoxic effects against tumor cells.Bupleurum falcatum shows a significant anti-cell adhesive activity on solid tumor cells and Curcuma longa has a relevant immunostimulatory activity.
The main natural products from Traditional Chinese Medicine
|Product||Type||Main property/ies||Studies in humans||RCTs||Meta-analysis||Ref.|
|Panax Ginseng||Herb||Anti-proliferation and angiogenesis||Yes||Yes||Yes||[37,38,55]|
|Bufotoxin||Toad skin secretion||Induces apoptosis||Yes||Yes||Yes||[39,55]|
|Bubleurum falcatum||Herb||Anti-adhesive activity||No||No||No|||
|Curcuma longa||Herb||Immunostimulatory activity||No||No||No|||
|Cinobufacini||Bufo skin estract||Induces apoptosis||Yes||Yes||No|||
|Sho-saiko-to*||Herb||Decreases collagene type 1||Yes||Yes||No||[7,45-48]|
Concerning the prevention ability of herbal products, a Japanese herb called Sho-saiko-to has to be cited since it is reported in the Asian-Pacific guidelines. In a randomized controlled trial (RCT), Sho-saiko-to was shown to improve liver function in patients with chronic hepatitis. Also Oka et al. reported that Sho-saiko-to may prevent the development of HCC in cirrhotic subjects. Successive studies with liver cell lines confirmed the above-cited suggestions.[47,48]
In 2013, Zhai et al. compared in a RCT the efficacy of TCM and TACE in preventing recurrence of small HCC after resection. Authors tested TACE or TCM as adjuvant therapy for patients who underwent surgery without evidence of recidivism. One hundred and eighty-eight patients received Cinobufacini injection (extract from Bufo bufo gargarizans Cantor) and Jiedu Granule (a compound herbal medicine). The other patients (191 cases) were assigned to the TACE subgroup. TCM was associated with decreased HCC recurrence after resection in comparison to TACE, with similar adverse events.
Regarding the use of TCM alone as therapeutic tool, Tian et al. demonstrated that it may be effective in subjects affected by middle/late stage HCC. In this RCT, 97 patients were treated with Oleum fructus bruceas, Ganji Decoction and external application of Ailitong, and 48 patients received chemotherapy. The HCC progression was similar between the two groups, but the TCM approach showed less adverse reactions. Moreover, survival rate at three months was comparable, while the test group had a better half- and 1-year survival.
Man et al. studied 94 patients with unresectable HCC. Authors compared three subgroups: (1) patients receiving TCM with non-curative antitumor treatments of Western Medicine; (2) patients receiving TCM alone; and (3) patients treated with non-curative antitumor treatments of Western Medicine or supportive treatment alone. They showed that patients treated with the combination schedule respect to patients in Western therapy alone, showed a significantly better 1- and 2-year survival (76.0% and 55.5% vs. 55.8% and 30.8%, respectively).
In 2005, Shu et al. analysed 26 RCTs reporting that TCM might determine an advantage in terms of both neoplasm response and long-term patient survival. Notably, authors did not specify the kind of used natural product. McCulloch et al. compared 34 RCTs, including 2,815 subjects, demonstrating that Astragalus-based TCM increased the efficacy of platinum chemotherapy. In 2009, two meta-analyses reported data concerning the possible role of TCM in association with TACE. Cho and Chen analyzed 30 studies showing an improved long-term survival in patients treated with the association between TACE and TCM respect to the subjects who did not receive TCM. According to this study, TCM determined a relevant increase in white blood cell count, a substantially lower nausea and vomiting, and a significant rise in the body weight. Wu et al. systematically reviewed and meta-analyzed a series of Chinese RCTs concerning the efficacy of TCM for the treatment of HCC. Authors reported some criticisms of the analyzed trials suggesting that the methodological issues were poor. Nevertheless, the studies with bufotoxin, astragalus (with or without mylabris) and ginseng associated to TACE, showed lower HCC recurrence and better patient survival in comparison to TACE alone. However, authors suggested that these data should be confirmed in further well-conducted Western RCTs.
Kanglaite (KLT) is a TCM coming from the seeds of a tropical Asian grass called Coix. It exhibits antitumor and immunomodulatory activity. Fu et al. performed a meta-analysis including nine clinical trials to evaluate the efficacy of KLT injection combined with hepatic arterial intervention for the treatment of unresectable HCC. KLT injection combined with hepatic arterial intervention respect to arterial therapy alone, seemed to improve both short-term clinical efficacy and pain’s control.
Cannabinoids are lipid mediators isolated from the hemp plant Cannabis sativa that can activate two G-protein-coupled receptors. The active ingredients of Cannabis, as well as their synthetic analogues, are bioactive lipids that seem to block cell proliferation, reduce cell migration and inhibit angiogenesis. The molecular mechanisms involved in the antineoplastic and anti-HCC action are debated. G protein-coupled receptor type 1 and 2 are typically considered the cannabinoids receptors. However, these substances may impact on other targets such as nuclear receptors peroxisome proliferator-activated receptor (PPAR)s. PPARs are ligand-activated transcription factors, which belong to the nuclear receptor superfamily and mediate lipid metabolism, energy balance and anti-inflammatory cascade. Several PPAR ligands have been shown to decrease HCC cell proliferation and migration through PPAR activation. Moreover, utilizing a PPARg knockout mice model, it was suggested that PPAR decreases HCC carcinogenesis acting as tumor-suppressor gene in the liver. Notably, the synthetic cannabinoid WIN 55,212-2 seemed to increase PPAR expression leading to apoptosis in the HCC HepG2 cell line. Vara et al. demonstrated that D9-tetrahydrocannabinol and JWH-015 (two kind of cannabinoids), might induce autophagy in HCC cells stimulating the AMP-activated protein kinase pathway. Jiang et al. studying the PPAR-deficient mice, demonstrated the accumulation of autophagic vacuoles and up-regulation of autophagic marker LC3 protein expression. These results are in agreement with the above reported observations by Vara et al. These authors suggested a connection between PPAR and autophagy-essential proteins in mammalian HCC. Also Vara et al. reported the involvement of PPAR activation in the anti-cancer effect of cannabinoids. The authors showed that THC and JWH-015 might increase mRNA and protein levels of PPAR inducing PPAR activation in vitro. Moreover, the authors showed that, when endoplasmic reticulum stress-related protein tribbles homolog 3 (TRIB 3) is genetically inhibited, the expression of both PPAR mRNA and protein decreased. Indeed, TRIB 3 seemed to have a significant role in regulating cannabinoid-induced PPAR overexpression. Cannabinoid treatment could improve phosphorylated-eIF2a (an endoplasmic reticulum stress marker) and the endoplasmic reticulum stress-related pseudokinase TRIB 3. Notably, this latter is necessary for cannabinoid-induced cell death and the consequent anti-tumor effect. Regarding the role of TRIB 3, Takahashi et al. demonstrated that it can downregulate PPAR transcriptional activities by protein-protein interaction in 3T3-L1 adipocytes.
HCC represents one of the most common cancers worldwide and is the third cause of neoplasm-related death. Since chronic viral hepatitis are the main risk factors for HCC, the vaccination against hepatitis B and the treatment of both hepatitis B and C, represent the main preventive therapies. Today, the potentially curative (LT, resection, ablation) and palliative (arterial chemoembolization, sorafenib) standards of care still do not protect from a relevant rate of mortality.
Cohort studies and meta-analyses suggest that high coffee intake might prevent the HCC in subgroups of patients at increased risk. Nevertheless, the mechanisms involved and the specific components of coffee beverages that may determine this sort of protection are unknown. The available studies often report different cut-offs of coffee intake, besides not taking into account many potential confounders. Moreover, registration of coffee consumption depends mainly on the self-reporting questionarries with intrinsic relevant statistical limits. Consequently, it is difficult to establish the temporal relationship between coffee use, liver disease and HCC onset. Indeed, the open questions are the following: how much coffee is necessary and for how long time? Which is the long-term safety profile of high-dose caffeine?
Concerning TCM, many authors proposed it, alone or in association with standard therapy. Notably, the studies proposing TCM approach alone for the treatment of HCC show no strong data. The TCM treatment obtains some interesting results if administered together with TACE. In particular, RCTs and meta-analyses demonstrate an advantage in terms of both patients’ survival and quality of life in comparison with the Western approach alone. However, there are many unclear aspects: which single product of the TCM large family is the best? Which is the impact of TCM on the liver function? Which is the safety profile of each TCM product?
Many basic studies suggest that cannabis could block cell proliferation, reduce cell migration and inhibit angiogenesis thus showing an anticancer attitude. Several data show a relationship between PPAR receptor and autophagy-essential proteins in HCC but the mechanisms involved in the antineoplastic action of cannabinoids are still debated. Furthermore, the lack of data on humans makes difficult to consider these substances as therapeutic choices.
It may be that the described natural products could have a future in the prevention of HCC, in the strengthening of the standard therapy and in the palliative phase. Still, further RCTs with strong results are mandatory for their effective broad application.
There are no conflicts of interest.
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.DOIPubMed
2. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepa- tocellular carcinoma in Europe, 1980-2004. Hepatology 2008;48:137-45.DOIPubMed
3. Chuang SC, La Vecchia C, Boffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett 2009;286:9-14.DOIPubMed
4. Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N, Milicevic M. Hepatocellular carcinoma: from clinical practice to evidence-based treatment protocols. World J Hepatol 2015;7:2274-91.DOIPubMedPMC
5. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.DOIPubMed
6. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.DOIPubMedPMC
7. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida HY, Kudo M, Lee JM, Choi BI, Poon RTP, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74.DOIPubMedPMC
8. La Vecchia C. Coffee, liver enzymes, cirrhosis and liver cancer. J Hepatol 2005;42:444-6.DOIPubMed
9. Cavin C, Holzhauser D, Constable A, Huggett AC, Schilter B. The coffee specific diterpenes cafestol and kahweol protect against aflatoxin B1-induced genotoxicity through a dual mechanism. Carcinogenesis 1998;19:1369-75.DOIPubMed
10. Majer BJ, Hofer E, Cavin C, Lhoste E, Uhl M, Glatt HR, Meinl W, Knasmüller S. Coffee diterpenes prevent the genotoxic effects of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and N-nitrosodimethylamine in a human derived liver cell line (HepG2). Food Chem Toxicol 2005;43:433-41.DOIPubMed
11. Huber WW, Parzefall W. Modification of N-acetyltransferases and glutathione S-transferases by coffee components: possible relevance for cancer risk. Methods Enzymol 2005;401:307-41.DOI
12. Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005;128:24-32.DOIPubMed
13. Casiglia E, Spolaore P, Ginocchio G, Ambrosio GB. Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol 1993;9:293-7.DOIPubMed
14. Klatsky AL, Armstrong MA. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol 1992;136:1248-57.DOIPubMed
15. Klatsky AL, Armstrong MA, Friedman GD. Coffee, tea, and mortality. Ann Epidemiol 1993;3:375-81.DOI
16. Kuper H, Tzonou A, Kaklamani E, Hsieh CC, Lagiou P, Adami HO, Trichopoulos D, Stuver SO. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000;85:498-502.DOI
17. La Vecchia C, Ferraroni M, Negri E, D'Avanzo B, Decarli A, Levi F, Franceschi F. Coffee consumption and digestive tract cancers. Cancer Res 1989;49:1049-51.PubMed
18. Gelatti U, Covolo L, Franceschini M, Pirali F, Tagger A, Ribero ML, Trevisi P, Martelli C, Nardi G, Donato F; Brescia HCC Study Group. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol 2005;42:528-34.DOIPubMed
19. Montella M, Polesel J, La Vecchia C, Dal Maso L, Crispo A, Crovatto M, Casarin P, Izzo F, Tommasi LG, Talamini R, Franceschi S. Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. Int J Cancer 2007;120:1555-9.DOIPubMed
20. Tanaka K, Hara M, Sakamoto T, Higaki Y, Mizuta T, Eguchi Y, Yasutake T, Ozaki I, Yamamoto K, Onohara S, Kawazoe S, Shigematsu H, Koizumi S. Inverse association between coffee drinking and the risk of hepatocellular carcinoma: a case-control study in Japan. Cancer Sci 2007;98:214-8.DOIPubMed
21. Ohfuji S, Fukushima W, Tanaka T, Habu D, Tamori A, Sakaguchi H, Takeda T, Kawada N, Seki S, Nishiguchi S, Shiomi S, Hirota Y. Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: a case-control study. Hepatol Res 2006;36:201-8.DOIPubMed
22. Leung WW, Ho SC, Chan HL, Wong V, Yeo W, Mok TSK. Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. J Epidemiol Community Health 2011;65:556-8.DOIPubMed
23. Inoue M, Yoshimi I, Sobue T, Tsugane S. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005;97:293-300.DOIPubMed
24. Inoue M, Kurahashi N, Iwasaki M, Shimazu T, Tanaka Y, Mizokami M, Tsugane S; Japan Public Health Center-Based Prospective Study Group. Effect of coffee and green tea consumption on the risk of liver cancer: cohort analysis by hepatitis virus infection status. Cancer Epidemiol Biomarkers Prev 2009;18:1746-53.DOIPubMed
25. Johnson S, Koh WP, Wang R, Govindarajan S, Yu MC, Yuan JM. Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Cancer Causes Control 2011;22:503-10.DOIPubMedPMC
26. Hu G, Tuomilehto J, Pukkala E, Hakulinen T, Antikainen R, Vartiainen E, Jousilahti P. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology 2008;48:129-36.DOIPubMed
27. Bravi F, Cristina Bosetti C, Alessandra Tavani A, Vincenzo Bagnardi V, Silvano Gallus S, Negri E, Franceschi S, La Vecchia C. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology 2007;46:430-5.DOIPubMed
28. Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 2007;132:1740-5.DOIPubMed
29. Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol 2013;11:1413-21.DOIPubMed
30. Bamia C, Lagiou P, Jenab M, Trichopoulou A, Fedirko V, Aleksandrova K, Pischon T, Overvad K, Olsen A, Tjønneland A, Boutron-Ruault MC, Fagherazzi G, Racine A, Kuhn T, Boeing H, Floegel A, Benetou V, Palli D, Grioni S, Panico S, Tumino R, Vineis P, Bueno-de-Mesquita HB, Dik VK, Bhoo-Pathy N, Uiterwaal CS, Weiderpass E, Lund E, Quirós JR, Zamora-Ros R, Molina-Montes E, Chirlaque MD, Ardanaz E, Dorronsoro M, Lindkvist B, Wallström P, Nilsson LM, Sund M, Khaw KT, Wareham N, Bradbury KE, Travis RC, Ferrari P, Duarte-Salles T, Stepien M, Gunter M, Murphy N, Riboli E, Trichopoulos D. Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. Int J Cancer 2015;136:1899-908.DOIPubMed
31. Setiawan VW, Wilkens LR, Lu SC, Hernandez BY, Le Marchand L, Henderson BE. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 2015;148:118-25.DOIPubMedPMC
32. Feld JJ, Lavoie éG, Michel F, Dranoff JA. I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. F1000Res 2015;4:95.
33. Petrick JL, Freedman ND, Graubard BI, Sahasrabuddhe VV, Lai GY, Alavanja MC, Beane-Freeman LE, Boggs DA, Buring JE, Chan AT, Chong DQ, Fuchs CS, Gapstur SM, Gaziano JM, Giovannucci EL, Hollenbeck AR, King LY, Koshiol J, Lee IM, Linet MS, Palmer JR, Poynter JN, Purdue MP, Robien K, Schairer C, Sesso HD, Sigurdson AJ, Zeleniuch-Jacquotte A, Wactawski-Wende J, Campbell PT, McGlynn KA. Coffee consumption and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma by sex: the Liver Cancer Pooling Project. Cancer Epidemiol. Biomarkers Prev 2015;24:1398-406.DOIPubMedPMC
34. Kurozawa Y, Ogimoto I, Shibata A, Nose T, Yoshimura T, Suzuki H, Sakata R, Fujita Y, Ichikawa S, Iwai N, Tamakoshi A; JACC Study Group. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer 2005;93:607-10.DOIPubMedPMC
35. Chu DT, Lepe-Zuniga J, Wong WL, LaPushin R, Mavligit GM. Fractionated extract of Astragalus membranaceus, a Chinese medicinal herb, potentiates LAK cell cytotoxicity generated by a low dose of recombinant interleukin-2. J Clin Lab Immunol 1988;26:183-7.PubMed
36. Chu DT, Wong WL, Mavligit GM. Immunotherapy with Chinese medicinal herbs. I. Immune restoration of local xenogeneic graft-versus-host reaction in cancer patients by fractionated Astragalus membranaceus in vitro. J Clin Lab Immunol 1988;25:119-23.PubMed
37. Shin HR, Kim JY, Yun TK, Morgan G, Vainio H. The cancer-preventive potential of Panax ginseng: a review of human and experimental evidence. Cancer Causes Control 2000;11:565-76.DOIPubMed
38. Keum YS, Park KK, Lee JM, Chun KS, Park JH, Lee SK, Kwon H, Surh YJ. Antioxidant and anti-tumor promoting activities of the methanol extract of heat-processed ginseng. Cancer Lett 2000;150:41-8.DOI
39. Jing Y, Ohizumi H, Kawazoe N, Hashimoto S, Masuda Y, Nakajo S, Yoshida T, Kuroiwa Y, Nakaya K. Selective inhibitory effect of bufalin on growth of human tumor cells in vitro: association with the induction of apoptosis in leukemia HL-60 cells. Jpn J Cancer Res 1994;85:645-51.DOIPubMed
40. Nogawa T, Kamano Y, Yamashita A, Pettit GR. Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese Traditional Drug Ch'an Su. J Nat prod 2001;64:1148-52.DOIPubMed
41. Huh JE, Kang KS, Ahn KS, Kim DH, Saiki I, Kim SH. Mylabris phalerlata induces apoptosis by caspase activation following cytochrome c release and Bid cleavage. Life Sci 2003;73:2249-62.DOI
42. Wang CC, Chen LG, Yang LL. Cytotoxic activity of sesquiterpenoids from Atractylodes ovata on leukemia cell lines. Planta Med 2002;68:204-8.DOIPubMed
43. Ahn BZ, Yoon YD, Lee YH, Kim BH, Sok DE. Inhibitory effect of bupleuri radix saponins on adhesion of some solid tumor cells and relation to hemolytic action: screening of 232 herbal drugs for anti-cell adhesion. Planta Med 1998;64:220-4.DOIPubMed
44. Antony S, Kuttan R, Kuttan G. Immunomodulatory activity of curcumin. Immunol Invest 1999;28:291-303.DOIPubMed
45. Hirayama C, Okumura M, Tanikawa K, Yano M, Mizuta M, Ogawa N. A multicenter randomized controlled clinical trial of Shosaiko-to in chronic active hepatitis. Gastroenterol Jpn 1989;24:715-9.PubMed
46. Oka H, Yamamoto S, Kuroki T, Harihara S, Marumo T, Kim SR, Monna T, Kobayashi K, Tango T. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995;76:743-9.DOI
47. Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, Yasuda M, Shiba M, Horie T, Amagaya S, Kawada N, Hori H, Ito S. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999;29:149-0.DOIPubMed
48. Shiota G, Maeta Y, Mukoyama T, Yanagidani A, Udagawa A, Oyama K, Yashima K, Kashimoto Y, Nakai Y, Miura T, Ito H, Murawaki Y, Kawasaki H. Effects of Sho-Saiko-to on hepatocarcinogenesis and 8-hydroxy-20-deoxyguanosine formation. Hepatology 2002;35:1125-33.DOIPubMed
49. Zhai XF, Chen Z, Li B, Shen F, Fan J, Zhou WP, Yang YK, Xu J, Qin X, Li LQ, Ling CQ. Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial. J Integr Med 2013;11:90-100.DOIPubMed
50. Tian HQ, Li HL, Wang B, Liang GW, Huang XQ, Huang ZQ, Lang JM, Zhang YP, Chen XZ, Chen YS. Treatment of middle/late stage primary hepatic carcinoma by Chinese medicine comprehensive therapy: a prospective randomized controlled study. Chin J Integr Med 2010;16:102-8.DOIPubMed
51. Man YN, Liu XH, Wu XZ. Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma. Chin J Integr Med 2015;21:49-57.DOIPubMed
52. Shu X, McCulloch M, Xiao H, Broffman M, Gao J. Chinese herbal medicine and chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Integr Cancer Ther 2005;4:219-29.DOI
53. McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, Gao J, Lieb W, Shieh K, Colford JM, Jr. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small- cell lung cancer: meta-analysis of randomized trials. J Clin Oncol 2006;24:419-30.DOIPubMed
54. Cho WC, Chen HY. Transcatheter arterial chemoembolization combined with or without Chinese herbal therapy for hepatocellular carcinoma: meta-analysis. Expert Opin Investig Drugs 2009;18:617-35.DOIPubMed
55. Wu P, Dugoua JJ, Eyawo O, Mills EJ. Traditional Chinese medicines in the treatment of hepatocellular cancers: a systematic review and meta-analysis. J Exp Clin Cancer Res 2009;28:112.DOIPubMedPMC
56. Fu F, Wan Y, Mulati, Wu T. Kanglaite injection combined with hepatic arterial intervention for unresectable hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther 2014;10:38-41.DOIPubMed
57. Vara D, Salazar M, Olea-Herrero N, Guzman M, Velasco G, Diaz-Laviada I. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ 2011;18:1099-111.DOIPubMedPMC
58. Velasco G, Sanchez C, Guzman M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 2012;12:436-44.DOIPubMed
59. O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator activated receptors. Br J Pharmacol 2007;152:576-82.DOIPubMedPMC
60. Yousse FJ, Badr M. Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol 2011;164:68-82.DOIPubMedPMC
61. Shen B, Chu ES, Zhao G, Man K, Wu CW, Cheng JT, Li G, Nie Y, Lo CM, Teoh N, Farrell GC, Sung JJ, Yu J. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice. Br J Cancer 2012;106:1486-94.DOIPubMedPMC
62. Yu J, Shen B, Chu ES, Teoh N, Cheung KF, Wu CW, Wang S, Lam CN, Feng H, Zhao J, Cheng AS, To KF, Chan HL, Sung JJ. Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Hepatology 2010;51:2008-19.DOIPubMed
63. Giuliano M, Pellerito O, Portanova P, Calvaruso G, Santulli A, De Blasio A, Vento R, Tesoriere G. Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: involvement of the transcription factor PPARgamma. Biochimie 2009;91:457-65.DOIPubMed
64. Jiang M, Fernandez S, Jerome WG, He Y, Yu X, Cai H, Boone B, Yi Y, Magnuson MA, Roy-Burman P, Matusik RJ, Shappell SB, Hayward SW. Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy. Cell Death Differ 2010;17:469-81.DOIPubMedPMC
65. Vara D, Morell C, Rodrıguez-Henche N, Diaz-Laviada I. Involvement of PPARc in the antitumoral action of cannabinoids on hepatocellular carcinoma. Cell Death Dis 2013;4:e618.DOIPubMedPMC
66. Salazar M, Hernandez-Tiedra S, Torres S, Lorente M, Guzman M, Velasco G. Detecting autophagy in response to ER stress signals in cancer. Methods Enzymol 2011;489:297-317.DOIPubMed
67. Takahashi Y, Ohoka N, Hayashi H, Sato R. TRB3 suppresses adipocyte differentiation by negatively regulating PPARgamma transcriptional activity. J Lipid Res 2008;49:880-92.DOIPubMed
Antonio Giorgio et al., Hepatoma Research, 2019
Efficacy and safety of stereotactic body radiation therapy combined with transarterial chemoembolization for Chinese intermediate-to advanced-stage hepatocellular carcinoma patients: a systematic review and meta-analysis
Shou-Jie Zhao et al., Hepatoma Research, 2019
Mauro Borzio et al., Hepatoma Research, 2019
Shinichiro Nakamura et al., Hepatoma Research, 2019
Xiao-Dong Zhang et al., Hepatoma Research, 2019
Jian-Guo Chen et al., Hepatoma Research, 2019
Yi Yang et al., Hepatoma Research, 2019
Wen-Bin Ding et al., Hepatoma Research, 2019
Tiong Sun Chia et al., Hepatoma Research, 2019
Zi-Xian Ma et al., Hepatoma Research, 2019